Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Open accessThe DOI matches its Crossref record; 265 of the 268 references it cites were found in a registry or an index.
Abstract
The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, SLNs utilize receptor-mediated and adsorptive-mediated transcytosis to cross the BBB and enable sustained drug release [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“SLNs can effectively transport drugs across the BBB, enabling the delivery of compounds that are otherwise impermeable [74].”
From Targeted Nanoparticles for Drug Delivery Across the Blood–Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review (2026) · cites this paper as [74]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759 · cited 3×
“These features make SLNs advantageous for production on a large industrial scale [43].”
InfluentialSacco, R. L., Kasner, S. E., Broderick, J. P., Caplan, L. R., Connors, J. J. (., Culebras, A., Elkind, M. S. V., George, M. G., Hamdan, A. D., Higashida, R. T., et al. (2013) · Stroke · doi:10.1161/str.0b013e318296aeca · Cited by 3,569 · cited 1×
“There are several types of ischemic strokes, such as lacunar, cardioembolic, and cryptogenic strokes, and hemorrhagic strokes [259].”
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Solid lipid nanoparticles Production, characterization and applications
Mehnert, W. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00105-3 · Cited by 3,150 · cited 2×
“SLNs can also be synthesized by ultrasonication [120,170,173] (Figure 7) in an easily assessable way, to overcome the limitations of high-shear homogenization.”
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders
Zlokovic, B. V. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3114 · Cited by 2,969 · cited 1×
“The essential neurovascular unit cell types that contribute to the functionality of the BBB are endothelial cell adhesion molecules, pericytes, smooth muscle cells, astrocytes, and micro glia, etc., which form the BBB, a complex barrier unit [13–16].”
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261 · cited 1×
“Besides this, the endothelial cells of the BBB also restrict active molecules from entering the brain by limiting pinocytic activity [83–85].”
The Role of Glutamate Neurotoxicity in Hypoxic-Ischemic Neuronal Death
Choi, D. W., & Rothman, S. M. (1990) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.13.030190.001131 · Cited by 2,223
Animal Communication: When I’m Calling You, Will You Answer Too?
Vickers, N. J. (2017) · Current Biology · doi:10.1016/j.cub.2017.05.064 · Cited by 2,210
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Synaptic Energy Use and Supply
Harris, J. J., Jolivet, R., & Attwell, D. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.019 · Cited by 1,747 · cited 1×
“The essential neurovascular unit cell types that contribute to the functionality of the BBB are endothelial cell adhesion molecules, pericytes, smooth muscle cells, astrocytes, and micro glia, etc., which form the BBB, a complex barrier unit [13–16].”
Hachinski, V., Iadecola, C., Petersen, R. C., Breteler, M. M., Nyenhuis, D. L., Black, S. E., Powers, W. J., DeCarli, C., Merino, J. G., Kalaria, R. N., et al. (2006) · Stroke · doi:10.1161/01.str.0000237236.88823.47 · Cited by 1,722 · cited 1×
“Multiple sclerosis (MS) disables the CNS along with the brain and spinal cord, where the insulating covers of nerve cells in the brain and spinal cord are deactivated and damaged [237].”
GLIOMA EXTENT OF RESECTION AND ITS IMPACT ON PATIENT OUTCOME
Sanai, N., & Berger, M. S. (2008) · Neurosurgery · doi:10.1227/01.neu.0000318159.21731.cf · Cited by 1,328 · cited 1×
“The main obstacle to this is the difficulty in the effective transport of anti-cancer drugs across the BBB, resulting in lower therapeutic efficacy [242,243].”
Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach
des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., & Préat, V. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.08.013 · Cited by 1,305 · cited 1×
“A broad range of drugs and their modifications have been investigated for their ability to treat glioblastoma, such as the SLNs of etoposide [205] and paclitaxel [206].”
Intranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214 · cited 1×
“Still, the intranasal route is not an ideal approach due to inconsistencies in the released dose at the target site, which is solely dependent on the nature of the nasal mucosa and its interaction with the drug [22,30].”
Astrocyte-endothelial Interactions and Blood-Brain Barrier Permeability*
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00064.x · Cited by 1,168
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 2×
“This leads to better protection against first pass metabolism [41,102,103].”
Inflammatory mechanisms in ischemic stroke: therapeutic approaches
Lakhan, S. E., Kirchgessner, A., & Hofer, M. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-97 · Cited by 1,072
Solid lipid nanoparticles: A modern formulation approach in drug delivery system
Mukherjee, S., Ray, S., & Thakur, R. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.57282 · Cited by 1,000 · cited 1×
“This colloidal nano-carrier was developed as a better substitute for polymeric nanoparticles and liposomes due to its solid lipid composition instead of an aqueous solution, to safeguard active-drug-counteracting biochemical degradation [45].”
Mehnert, W., & Mäder, K. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.021 · Cited by 981
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 958
Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism
zur Mühlen, A., Schwarz, C., & Mehnert, W. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00150-1 · Cited by 945 · cited 1×
“• Provide opportunities for targeted and controlled release of drug [60,62,63].”
Transparent Water-in-Oil Dispersions: the Oleopathic Hydro-Micelle
HOAR, T. P., & SCHULMAN, J. H. (1943) · Nature · doi:10.1038/152102a0 · Cited by 884
Levin, V. A. (1980) · Journal of Medicinal Chemistry · doi:10.1021/jm00180a022 · Cited by 813 · cited 2×
“Several factors are responsible for drugs crossing the BBB, such as drug-related factors; molecular weight (below 400 Da), morphology (spherical), size (nano meter range), ionization (physiological pH), lipophilicity are the major factors [20].”
InfluentialFormulation strategy and use of excipients in pulmonary drug delivery
Pilcer, G., & Amighi, K. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.03.017 · Cited by 791
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Evaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744
Nanoparticles for direct nose-to-brain delivery of drugs
Mistry, A., Stolnik, S., & Illum, L. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.06.019 · Cited by 734 · cited 1×
“The active drug, loaded in some nanocarrier system after reaching the nasal cavity, directly reaching the brain through the olfactory pathway and trigeminal pathway [27–29].”
Nanostructured lipid carriers (NLC) in cosmetic dermal products☆
MULLER, R., PETERSEN, R., HOMMOSS, A., & PARDEIKE, J. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.012 · Cited by 700
Freitas, C., & Müller, R. H. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00092-1 · Cited by 687 · cited 2×
“They play a significant role in crossing the reticuloendothelial system (RES) of the BBB [42–44].”
Delivery of therapeutic agents to the central nervous system: the problems and the possibilities
Begley, D. J. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.08.001 · Cited by 679 · cited 1×
“The BBB is an anatomical protective barrier to the brain which separates the brain from direct contact with the blood [9].”
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677 · cited 1×
“Donepezil, galantamine, and rivastigmine are the FDA-approved drugs use as acetylcholinesterase inhibitors to treat various grades of AD [220].”
CNS Delivery Via Adsorptive Transcytosis
Hervé, F., Ghinea, N., & Scherrmann, J.-M. (2008) · The AAPS Journal · doi:10.1208/s12248-008-9055-2 · Cited by 676 · cited 7×
“The endocytic vesicles, which play a major role in this RMT, are clathrin-coated pits, caveolae, and macropinocytosis vesicles.”
InfluentialSolid Lipid Nanoparticles: Emerging Colloidal Nano Drug Delivery Systems
Mishra, V., Bansal, K. K., Verma, A., Yadav, N., Thakur, S., Sudhakar, K., & Rosenholm, J. M. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040191 · Cited by 669 · cited 1×
“…butanol)preservatives (thiomersal), cryoprotectants (gelatin, glucose, mannose, maltose, lactose, sorbitol, mannitol, glycine, polyvinyl alcohol, polyvinyl pyrrolidone), and charge modifiers (dipalmitoyl phosphatidyl choline, stearylamine, dicetylphosphate, dimyristoyl phophatidyl glycerol) [121].”
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Influence of microemulsions on cutaneous drug delivery
Kreilgaard, M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00116-3 · Cited by 629
Modelling of the blood–brain barrier in drug discovery and development
Cecchelli, R., Berezowski, V., Lundquist, S., Culot, M., Renftel, M., Dehouck, M.-P., & Fenart, L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2368 · Cited by 618 · cited 1×
“The main BBB components are endothelial cells, astrocytic end-feet links, basal lamina, tight junctions, and pericytes [10–12] (Figure 1).”
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615 · cited 1×
“SLNs have a solid hydrophobic lipid core, in which both hydrophilic and lipophilic drugs can be dispersed [40,41].”
Property-Based Design: Optimization of Drug Absorption and Pharmacokinetics
van de Waterbeemd, H., Smith, D. A., Beaumont, K., & Walker, D. K. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm000407e · Cited by 599 · cited 1×
“0), enzymatic stability, plasma-proteinbinding affinity, uptake of the drug into other tissues, volume of distribution, clearance rate, and rate of oxidative metabolism by cytochrome P450 effects [20,21].”
Lipid nanocapsules: A new platform for nanomedicine
Huynh, N. T., Passirani, C., Saulnier, P., & Benoit, J. P. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.026 · Cited by 595
Schwarz, C., Mehnert, W., Lucks, J. S., & Müller, R. H. (1994) · Journal of Controlled Release · doi:10.1016/0168-3659(94)90047-7 · Cited by 574 · cited 1×
“However, the burst release can be controlled by replacing the smaller drugs with larger ones, such as lipid microparticles, and depending upon the properties of the surfactants used during formulation [118].”
Insulin in the brain: There and back again
Banks, W. A., Owen, J. B., & Erickson, M. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.006 · Cited by 574 · cited 1×
“For example, organic cation and anion transporters, GLUT-1, and large neutral amino acid transporters (LAT), play an important role in the delivery of various biomolecules [84,86,87] and their substrates in a size- and stereo-selective manner [88].”
Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation
Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549 · cited 2×
“The formed vesicles cross the cell to release the ligand to its basolateral side using exocytosis [91].”
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539 · cited 1×
“Lipid-based nanoparticles can pass the BBB in a safe and effective manner [35].”
Westesen, K., Bunjes, H., & Koch, M. H. J. (1997) · Journal of Controlled Release · doi:10.1016/s0168-3659(97)00046-1 · Cited by 536 · cited 1×
“During storage of SLNs, there may be chances of drug expulsion following polymeric transition [68,69].”
Thi, T. T. H., Suys, E. J. A., Lee, J. S., Nguyen, D. H., Park, K. D., & Truong, N. P. (2021) · Vaccines · doi:10.3390/vaccines9040359 · Cited by 525
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.4.554 · Cited by 497 · cited 1×
“These factors will be considered in relation to drug discovery in general and CNS drug discovery in particular [37].”
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Nanoparticles synthesis using supercritical fluid technology – towards biomedical applications
Byrappa, K., Ohara, S., & Adschiri, T. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.09.001 · Cited by 487 · cited 1×
“Particle aggregation is the main limitation of this process, which occurs due to the high temperature, shear forces and partial melting of the particle [129].”
Freitas, C., & Müller, R. H. (1999) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(98)00074-5 · Cited by 483 · cited 1×
“Comparing with polymeric nanoparticles, SLNs prohibit leakage and protect the active drug component from degradation (photochemical, oxidative, and chemical degradation) by immobilizing within and resulting a stable formulation [44,56].”
Kappos, L., Gold, R., Miller, D. H., MacManus, D. G., Havrdova, E., Limmroth, V., Polman, C. H., Schmierer, K., Yousry, T. A., Yang, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61619-0 · Cited by 482 · cited 1×
“Therefore, the failure of signal transmission in the brain results in a range of devastating physical, mental, and psychiatric problems [238–240].”
Transcytosis to Cross the Blood Brain Barrier, New Advancements and Challenges
Pulgar, V. M. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.01019 · Cited by 482 · cited 3×
“The steps involved in this process are as follows: endocytosis, intracellular vesicular trafficking and exocytosis [90].”
Delivery of peptides and proteins through the blood–brain barrier
Bickel, U., Yoshikawa, T., & Pardridge, W. M. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00139-3 · Cited by 481 · cited 1×
“The basic mechanism of AMT is based on the electrostatic interaction between the charged molecule, such as the positively charged protein and negatively charged luminal membrane of the brain endothelial cells [95,96].”
Selective expression of the large neutral amino acid transporter at the blood–brain barrier
Boado, R. J., Li, J. Y., Nagaya, M., Zhang, C., & Pardridge, W. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12079 · Cited by 481 · cited 1×
“For example, organic cation and anion transporters, GLUT-1, and large neutral amino acid transporters (LAT), play an important role in the delivery of various biomolecules [84,86,87] and their substrates in a size-and stereo-selective manner [88].”
Nanosuspensions for the formulation of poorly soluble drugs
Müller, R. H., & Peters, K. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(97)00311-6 · Cited by 480
Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., & Yang, C. Z. (1999) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00007-3 · Cited by 476 · cited 4×
“However, the formulation has been used to stabilize the physiological pH and further stabilize size, charge, and pharmacokinetics using SLN modifications, showing better brain targeting efficacy [49,73–75].”
InfluentialSelf-citationRego, A. C., & Oliveira, C. R. (2003) · Neurochemical Research · doi:10.1023/a:1025682611389 · Cited by 472
Getting into the Brain: Approaches to Enhance Brain Drug Delivery
Patel, M. M., Goyal, B. R., Bhadada, S. V., Bhatt, J. S., & Amin, A. F. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00003 · Cited by 461 · cited 2×
“Still, the intranasal route is not an ideal approach due to inconsistencies in the released dose at the target site, which is solely dependent on the nature of the nasal mucosa and its interaction with the drug [22,30].”
Müller, R. H., Mehnert, W., Lucks, J. S., Schwarz, C., Mühlen, A. Z., Meyhers, H., de Freitas, C. F., & Rühl, D. (1995) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 455
Schubert, M. (2003) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00130-3 · Cited by 454
Shinoda, K., & Saito, H. (1969) · Journal of Colloid and Interface Science · doi:10.1016/s0021-9797(69)80012-3 · Cited by 451
Gänger, S., & Schindowski, K. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10030116 · Cited by 447
Drug transport to brain with targeted nanoparticles
Olivier, J.-C. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.108 · Cited by 444 · cited 1×
“If the hydrophobic nature of the nanoparticle containing the drug can be shielded, it will be sterically stabilized, thus avoiding opsonization, and further increasing the blood circulation time and hence the bioavailability [101].”
Preparation of solid lipid nanoparticles by a solvent emulsification–diffusion technique
Trotta, M., Debernardi, F., & Caputo, O. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00135-2 · Cited by 439
Drug and gene targeting to the brain with molecular trojan horses
Pardridge, W. M. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd725 · Cited by 439 · cited 1×
“…lipid (LDL) (B16 melanoma cell line shows higher expression of LDL receptors), and peptide receptors (such as somatostatin analogs, vasoactive intestinal peptide, gastrin-related peptides, cholecystokinin, gluteinizing hormone releasing hormone), leading to increased selectivity [108,109].”
The production and characteristics of solid lipid nanoparticles (SLNs)
Hou, D., Xie, C., Huang, K., & Zhu, C. (2003) · Biomaterials · doi:10.1016/s0142-9612(02)00578-1 · Cited by 437
Colloidal drug delivery systems
Duncan-Hewitt, W. C. (1995) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/0927-7765(95)90010-1 · Cited by 419
Therapeutic Applications of Curcumin Nanoformulations
Yallapu, M. M., Nagesh, P. K. B., Jaggi, M., & Chauhan, S. C. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9811-z · Cited by 392
Manjunath, K., & Venkateswarlu, V. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.06.006 · Cited by 380 · cited 1×
“Some study findings show that the pharmacokinetics, tissue distribution, and bioavailability of SLNs loaded with nitrendipine (antipsychotic drug) could be improved by administering ni-trendipine SLN in rats [50].”
Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics
Bourganis, V., Kammona, O., Alexopoulos, A., & Kiparissides, C. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.05.009 · Cited by 357
Alyautdin, R. N., Petrov, V. E., Langer, K., Berthold, A., Kharkevich, D. A., & Kreuter, J. (1997) · Pharmaceutical Research · doi:10.1023/a:1012098005098 · Cited by 352 · cited 1×
“Polysorbate (20, 60, 80)-coated SLNs showed an enhanced pharmacological effect through its easy transportation across the BBB via endocytosis triggered by apolipoprotein [103,104].”
Loureiro, J., Andrade, S., Duarte, A., Neves, A., Queiroz, J., Nunes, C., Sevin, E., Fenart, L., Gosselet, F., Coelho, M., et al. (2017) · Molecules · doi:10.3390/molecules22020277 · Cited by 341 · cited 1×
“Interestingly, in vitro studies showed that AD and PD associated with severe neurodegeneration could be treated by resveratrol (a natural polyphenolic flavonoid) and grape-extract-loaded solid lipid nanoparticles, which enhance the regeneration of damaged neurons through crossing the BBB [274,275].”
Body Distribution of Camptothecin Solid Lipid Nanoparticles After Oral Administration
Yang, S., Zhu, J., Lu, Y., Liang, B., & Yang, C. (1999) · Pharmaceutical Research · doi:10.1023/a:1018888927852 · Cited by 324 · cited 2×
“However, the formulation has been used to stabilize the physiological pH and further stabilize size, charge, and pharmacokinetics using SLN modifications, showing better brain targeting efficacy [49,73–75].”
Self-citationFundarò, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0695 · Cited by 317 · cited 1×
“• SLNs can encapsulate both hydrophilic and lipophilic drugs [41,57,58].”
Paclitaxel nanoparticles for the potential treatment of brain tumors
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.006 · Cited by 299 · cited 1×
“The SLN formulation of paclitaxel (anticancer drug) stabilized with Brij 78 has shown better drug distribution in the brain in comparison to naïve drug, probably followed by P-gp-efflux-mediated brain drug delivery [81].”
Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.01.002 · Cited by 296 · cited 1×
“This leads to better protection against first pass metabolism [41,102,103].”
Hu, F. Q., Yuan, H., Zhang, H. H., & Fang, M. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00081-9 · Cited by 284
Moghimi, S. M., Porter, C. J. H., Muir, I. S., Illum, L., & Davis, S. S. (1991) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(91)91869-e · Cited by 282 · cited 1×
“The SLNs should be small enough or, if it is able to deform itself, it can avoid the splenic filtration process at the interendothelial cell slits (IES) [98,99].”
Spray-drying of solid lipid nanoparticles (SLNTM)
Freitas, C., & Müller, R. H. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00172-0 · Cited by 282
Smith, A., Giunta, B., Bickford, P. C., Fountain, M., Tan, J., & Shytle, R. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.012 · Cited by 280 · cited 1×
“In vivo [197] Curcumin loaded SLN”
Sun, J., Bi, C., Chan, H. M., Sun, S., Zhang, Q., & Zheng, Y. (2013) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2013.06.032 · Cited by 277 · cited 1×
“Disadvantages of SLNs. • Poor drug loading due to limited space in the lipid matrix [64–67].”
Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules
Garcı́a-Fuentes, M., Torres, D., & Alonso, M. J. (2003) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/s0927-7765(02)00053-x · Cited by 273
The Role of the Sinus Wall in the Passage of Erythrocytes Through the Spleen
Chen, L.-T., & Weiss, L. (1973) · Blood · doi:10.1182/blood.v41.4.529.529 · Cited by 269 · cited 2×
“The endothelial cells’ slit width from 200 to 500 nm in width [98].”
Brain uptake of thiamine-coated nanoparticles
Lockman, P. R., Oyewumi, M. O., Koziara, J. M., Roder, K. E., Mumper, R. J., & Allen, D. D. (2003) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.08.006 · Cited by 259 · cited 3×
“Ligand-conjugated SLNs show a higher retention of drug molecules at the BBB [60].”
Dhawan, S., Kapil, R., & Singh, B. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01225.x · Cited by 256 · cited 1×
“In vivo study [191] Galantamine loaded SLN Enhanced bioavailability and improved drug delivery In vitro [192] Quercetin-loaded SLN Reverse neurodegeneration In vivo [193] Piperine loaded SLN”
Antioxidants as treatment for neurodegenerative disorders
Moosmann, B., & Behl, C. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.10.1407 · Cited by 252 · cited 1×
“Oxidative stress is a general hallmark of major neurodegenerative disorders, leading to neuronal cell dysfunction and progressive death [270].”
Preparation of solid lipid nanoparticles using a membrane contactor
Charcosset, C., El-Harati, A., & Fessi, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.023 · Cited by 250
Solid Lipid Nanoparticles: A Review
., S. C. V., ., S. V., & ., U. U. (2011) · Journal of Current Pharma Research · doi:10.33786/jcpr.2011.v01i04.009 · Cited by 249
Diazepam-Loaded Solid Lipid Nanoparticles: Design and Characterization
Abdelbary, G., & Fahmy, R. H. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-009-9197-2 · Cited by 246
CHEN, D.-B., YANG, T.-Z., LU, W.-L., & ZHANG, Q. (2001) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.49.1444 · Cited by 243 · cited 4×
“SLNs can encapsulate both hydrophilic and lipophilic drugs [41,57,58].”
InfluentialNeves, A. R., Queiroz, J. F., & Reis, S. (2016) · Journal of Nanobiotechnology · doi:10.1186/s12951-016-0177-x · Cited by 240 · cited 1×
“Hence, this functionalized SLN drug carrier showed better BBB permeability in in vitro cell model [268].”
Jose, S., Anju, S. S., Cinu, T. A., Aleykutty, N. A., Thomas, S., & Souto, E. B. (2014) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2014.08.003 · Cited by 237 · cited 1×
“Another study aiming to enhance permeation through an in vitro BBB model, looked at the SLNs loaded with resveratrol functionalized with a targeting moiety, proving their inherent ability to passively target the brain [252].”
SCHWARZ, C. (1999) · Journal of Microencapsulation · doi:10.1080/026520499289185 · Cited by 235 · cited 1×
“On the other hand, there is a chance polymeric nanoparticles accumulate in the liver, spleen etc. [55].”
Production of lipospheres as carriers for bioactive compounds
Cortesi, R. (2002) · Biomaterials · doi:10.1016/s0142-9612(01)00362-3 · Cited by 233
Transporters at CNS Barrier Sites: Obstacles or Opportunities for Drug Delivery?
Sanchez-Covarrubias, L., Slosky, L., Thompson, B., Davis, T., & Ronaldson, P. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990463 · Cited by 231 · cited 2×
“…drug molecules and their modifications can also pass through the BBB using these efflux mediated proteins i.e., P-glycoproteins (P-gp or ABCB1, MDR1 gene product), breast cancer resistance proteins (BCRP/ABCG2), and the multidrug resistance-associated proteins (MRP1, 2, 4, and 5, ABCC) [84].”
Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies
Pires, P. C., & Santos, A. O. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.11.047 · Cited by 228 · cited 1×
“Intranasal route of drug delivery is also promising, allowing the drug to directly reach the brain by bypassing the BBB [24–26].”
CHATTOPADHYAY, P., SHEKUNOV, B., YIM, D., CIPOLLA, D., BOYD, B., & FARR, S. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.010 · Cited by 227
Kakkar, V., Muppu, S. K., Chopra, K., & Kaur, I. P. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.02.005 · Cited by 222 · cited 1×
“The SLNs loaded with curcumin (as an antioxidant) have also gained particular interest in terms of their use in stroke treat-ment [266].”
Molecular Biology of the Blood–Brain Barrier
Pardridge, W. M. (2005) · Molecular Biotechnology · doi:10.1385/mb:30:1:057 · Cited by 220 · cited 1×
“The selective transportation of nutrients or drugs across the BBB occurs through a specialized transportation across the capillary endothelial plasma membrane comprising active efflux systems, active transporters, and ectoenzymes [19].”
Cholinergic enhancement of frontal lobe activity in mild cognitive impairment
Saykin, A. J., Wishart, H. A., Rabin, L. A., Flashman, L. A., McHugh, T. L., Mamourian, A. C., & Santulli, R. B. (2004) · Brain · doi:10.1093/brain/awh177 · Cited by 216 · cited 1×
“Its therapeutics are based on targeting cholinergic dysfunction in developing cholinesterase inhibitors [219].”
Solid lipid based nanocarriers: An overview / Nanonosači na bazi čvrstih lipida: Pregled
Pardeshi, C., Rajput, P., Belgamwar, V., Tekade, A., Patil, G., Chaudhary, K., & Sonje, A. (2012) · Acta Pharmaceutica · doi:10.2478/v10007-012-0040-z · Cited by 214 · cited 1×
“They play a significant role in crossing the reticuloendothelial system (RES) of the BBB [42–44].”
Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson???s Disease
Jankovic, J., & Stacy, M. (2007) · CNS Drugs · doi:10.2165/00023210-200721080-00005 · Cited by 213 · cited 1×
“However, the required drug bioavailability is unsatisfactory [232,233], with lower therapeutic efficacy.”
Kakkar, V., & Kaur, I. P. (2011) · Food and Chemical Toxicology · doi:10.1016/j.fct.2011.08.006 · Cited by 212 · cited 2×
“This was employed in the microemulsification technique for the treatment of [198] aluminum-induced AD.”
Intracellular transport and regulation of transcytosis across the blood–brain barrier
Villaseñor, R., Lampe, J., Schwaninger, M., & Collin, L. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2982-x · Cited by 209 · cited 3×
“(3) Receptor-mediated transcytosis (RMT) RMT-mediated transport is a specialized transport system by which endogenous molecules can cross the BBB for brain delivery by the activation of peripheral brain endothelial cells [89].”
Zara, G. P., Cavalli, R., Bargoni, A., Fundarò, A., Vighetto, D., & Gasco, M. R. (2002) · Journal of Drug Targeting · doi:10.1080/10611860290031868 · Cited by 207 · cited 1×
“Better results were found with increasing amounts of stealth agents, resulting in a longer blood circulation time in case of SLN-doxorubicin stealth [57,105–107].”
Albumin microspheres for study of the reticuloendothelial system.
Scheffel, U., Rhodes, B. A., Natarajan, T. K., & Wagner, H. N. (1972) · PubMed · Cited by 207
Westesen, K., Siekmann, B., & Koch, M. H. J. (1993) · International Journal of Pharmaceutics · doi:10.1016/0378-5173(93)90177-h · Cited by 206 · cited 1×
“During storage of SLNs, there may be chances of drug expulsion following polymeric transition [68,69].”
Sandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8261-y · Cited by 204 · cited 1×
“Curcumin-loaded SLNs are one such candidate; they were tested in vivo for the treatment of HD, reducing the severity [203].”
Baek, J.-S., & Cho, C.-W. (2017) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2017.04.013 · Cited by 204 · cited 1×
“The bioavailability of hydrophobic drugs is improved when they are in SLNs formulation in comparison to polymeric nanoparticles due to the physiological stability of the lipids [59].”
Solid Lipid Nanoparticles (SLN): Method, Characterization and Applications
Garud, A., Singh, D., & Garud, N. (2012) · International Current Pharmaceutical Journal · doi:10.3329/icpj.v1i11.12065 · Cited by 202 · cited 1×
“SLNs escape RES bypassing liver and spleen filtration due to their unique physicochemical properties [53,54].”
A Review of Nanocarrier-Based CNS Delivery Systems
Tiwari, S., & Amiji, M. (2006) · Current Drug Delivery · doi:10.2174/156720106776359230 · Cited by 200 · cited 1×
“…lipid (LDL) (B16 melanoma cell line shows higher expression of LDL receptors), and peptide receptors (such as somatostatin analogs, vasoactive intestinal peptide, gastrin-related peptides, cholecystokinin, gluteinizing hormone releasing hormone), leading to increased selectivity [108,109].”
Garcion, E., Lamprecht, A., Heurtault, B., Paillard, A., Aubert-Pouessel, A., Denizot, B., Menei, P., & Benoît, J.-P. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0289 · Cited by 198 · cited 1×
“A broad range of drugs and their modifications have been investigated for their ability to treat glioblastoma, such as the SLNs of etoposide [205] and paclitaxel [206].”
Development and application of high throughput plasma stability assay for drug discovery
Di, L., Kerns, E. H., Hong, Y., & Chen, H. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.03.022 · Cited by 193 · cited 1×
“There are various drug formulations that, despite their ability to cross the BBB, show poor plasma stability, rapid clearance, and a short half-life, resulting in poor in vivo efficacy [70].”
Wang, J., Wang, H., Zhu, R., Liu, Q., Fei, J., & Wang, S. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.02.116 · Cited by 187
Self-citationNeurofilament light as a prognostic marker in multiple sclerosis
Salzer, J., Svenningsson, A., & Sundström, P. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458509359725 · Cited by 187
Solid Lipid Nanoparticles as Delivery Systems for Bromocriptine
Esposito, E., Fantin, M., Marti, M., Drechsler, M., Paccamiccio, L., Mariani, P., Sivieri, E., Lain, F., Menegatti, E., Morari, M., et al. (2008) · Pharmaceutical Research · doi:10.1007/s11095-007-9514-y · Cited by 183 · cited 3×
“In vitro [199] Bromocriptine loaded SLN To stabilize plasma levels and increase CNS drug concentration and half-life In vivo [200] Rotigotine loaded SLN aerosol Oral inhalation improvement In vitro [200] Apomorphine loaded SLN Oral administration to increase bioavailability In vitro [201]…”
InfluentialTranscytosis of Macromolecules at the Blood–Brain Barrier
Preston, J. E., Joan Abbott, N., & Begley, D. J. (2014) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.06.001 · Cited by 182 · cited 1×
“The major receptors involved in RMT are transferrin receptor (TfR), insulin and insulin like growth factor receptor, low-density lipoprotein receptor (LDLR), low-density lipoprotein -receptor-related protein 1 and 2 (LRP1 and LRP2), scavenger receptor class B type I (SR-B1), leptin receptor, albumin receptor [90,92],…”
Hamdani, J. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(03)00229-1 · Cited by 180 · cited 1×
“SLNs containing drug also show a sustained release feature due to the use of solid lipids, modified drugs, and additive ingredients in a particular ratio, providing a particular physicochemical state with the longest diffusion pathway and controlled drug release [47–49].”
クリノアタカマイトCu 2 (OH) 3 ClとテノライトCuOナノ粒子のpH制御選択合成
Engelbrekt, C., Phillip, M., Jonas, A., Lijuan, Z., Kenny, S., Li, B., Jun, H., & Zhang, J. (2014) · Cited by 180
Wang, J.-X., Sun, X., & Zhang, Z.-R. (2002) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(02)00083-8 · Cited by 179 · cited 1×
“5-fluoro-2 ′ -deoxyuridine (FUdR) to the brain, 3 ′ ,5 ′ -dioctanoyl-5-fluoro-2 ′ -deoxyuridine (DO-FUdR) incorporated into solid lipid nanoparticles (DO-FUdR-SLN), has shown good brain-targeting efficacy for CNS disorders, shown in the studies by Wang et al. [77].”
Self-citationTsai, M.-J., Wu, P.-C., Huang, Y.-B., Chang, J.-S., Lin, C.-L., Tsai, Y.-H., & Fang, J.-Y. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.12.009 · Cited by 177 · cited 1×
“Another study focused on SLNs containing baicalin, and their actions against ischemic stroke, revealing the neuroprotective properties of encapsulated baicalin with improved bioavailability and stability [267].”
Olbrich, C., Gessner, A., Kayser, O., & Müller, R. H. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000001832 · Cited by 175 · cited 1×
“Ex-Witepsol W35 SLN dispersions [172] are produced by this method.”
Bondì, M. L., Craparo, E. F., Giammona, G., & Drago, F. (2010) · Nanomedicine · doi:10.2217/nnm.09.67 · Cited by 175 · cited 2×
“Multiple Sclerosis Riluzole loaded SLN A higher capability to carry the drug into the brain and a lower indiscriminate biodistribution In vivo [80]”
Leslie-Barbick, J. E., Saik, J. E., Gould, D. J., Dickinson, M. E., & West, J. L. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.060 · Cited by 174 · cited 2×
“The study demonstrated that the specialized SLN has anti-proliferative activity in targeting malignant glioblastoma cells [245].”
Yusuf, M., Khan, M., Khan, R. A., & Ahmed, B. (2013) · Journal of Drug Targeting · doi:10.3109/1061186x.2012.747529 · Cited by 171 · cited 2×
“Piperine loaded in SLN is another anti-AD drug studied in vivo by Yusuf et al. [194].”
Senthil Kumar, C., Thangam, R., Mary, S. A., Kannan, P. R., Arun, G., & Madhan, B. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2019.115682 · Cited by 168 · cited 1×
“…studies are based on how to attaching a targeting ligand to an SLN, such as by linking a fatty acid of the NP to an amino group of the ligand [113], an amino group of a phospholipid to an acid group of the ligand [114], or an amino group of the chitosan coating to an acid group of the ligand [115].”
Preparation and characterization of solid lipid nanospheres containing paclitaxel
Cavalli, R., Caputo, O., & Gasco, M. R. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00081-6 · Cited by 167 · cited 2×
“Other examples of hydrophilic compounds such as Brij 78, Poloxamer F68, and Brij 68, when coated with the paclitaxel-SLN formulation, show significantly increased drug bioavailability during i.v. injection in comparison to the plain drug [97].”
Eldem, T., Speiser, P., & Hincal, A. (1991) · Pharmaceutical Research · doi:10.1023/a:1015874121860 · Cited by 165 · cited 1×
“SLNs can also be synthesized by ultrasonication [120,170,173] (Figure 7) in an easily assessable way, to overcome the limitations of high-shear homogenization.”
Martins, S., Costa-Lima, S., Carneiro, T., Cordeiro-da-Silva, A., Souto, E. B., & Ferreira, D. C. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.03.032 · Cited by 165 · cited 1×
“Further research on SLNs of cetyl palmitate, stabilized with Tween ® 60 or Tween ® 80, carried out internalization studies in vitro and in vivo, and the results showed that the nanoparticles were internalized, leading to the increased therapeutic efficacy of the drug in crossing the BBB [251].”
Bhatt, R., Singh, D., Prakash, A., & Mishra, N. (2015) · Drug Delivery · doi:10.3109/10717544.2014.880860 · Cited by 159 · cited 1×
“Bhatt et al. studied a rosmarinic-acid-loaded SLN carrier’s intranasal administration [204] for HD, looking at its neuroprotective qualities.”
Recent Advances and Patents on Solid Lipid Nanoparticles
Sawant, K. K., & Dodiya, S. S. (2008) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221108784534081 · Cited by 158 · cited 1×
“Progressively, newly formed lipid nanoparticles have overcome the shortcomings of previous SLNs [8].”
Saini, S., Sharma, T., Jain, A., Kaur, H., Katare, O. P., & Singh, B. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111838 · Cited by 155 · cited 1×
“Via nose-to-brain in goat ex vivo, in vivo, and preclinical study [190] SLNs sesamol”
Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases
Cacciatore, I., Ciulla, M., Fornasari, E., Marinelli, L., & Di Stefano, A. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1178237 · Cited by 153 · cited 2×
“Idebenone is another antioxidant drug of choice, loaded into SLN as a potent drug delivery system to the brain [152,228].”
Application of lipid nanoparticles to ocular drug delivery
Battaglia, L., Serpe, L., Foglietta, F., Muntoni, E., Gallarate, M., Del Pozo Rodriguez, A., & Solinis, M. A. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1201059 · Cited by 152 · cited 1×
“SLNs, as unique delivery systems encapsulating active pharmaceuticals for the treatment of CNS disorders, can be delivered via oral, inhalational, and parenteral routes [188] to reach the neuronal sites.”
Picone, P., Bondi, M. L., Picone, P., Bondi, M. L., Montana, G., Bruno, A., Pitarresi, G., Giammona, G., & Di Carlo, M. (2009) · Free Radical Research · doi:10.1080/10715760903214454 · Cited by 151 · cited 1×
“In vivo [194] SLN carrying phosphatidic acid or cardiolipin High affinity for the A β peptide In vitro [195] Ferulic acid loaded SLN Overcome permeability issues and reduce oxidative stress in A β -treated cells In vitro [196] Epigallocatechin3-gallate”
Martins, S. M., Sarmento, B. F. C. C., Nunes, C., Lúcio, M., Reis, S., & Ferreira, D. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.08.011 · Cited by 150
Madan, J., Pandey, R. S., Jain, V., Katare, O. P., Chandra, R., & Katyal, A. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.10.003 · Cited by 146 · cited 1×
“Another study showed that the plasma half-life of the drug noscapine was enhanced by surface PEGylation, which could escape RES uptake [78].”
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Barchet, T. M., & Amiji, M. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902758188 · Cited by 145 · cited 1×
“Less successful treatment strategies have been developed to date for the treatment of neurodegenerative diseases [6].”
Production of solid lipid nanoparticles (SLN): scaling up feasibilities
Dingler, A., & Gohla, S. (2002) · Journal of Microencapsulation · doi:10.1080/02652040010018056 · Cited by 145
Nanotechnology for Delivery of Drugs to the Brain for Epilepsy
Bennewitz, M. F., & Saltzman, W. M. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.01.018 · Cited by 142 · cited 1×
“Among the conventional and recently developed drug delivery strategies, a nano-technological SLN based approach has shown possible advancements in overcoming the existing limitations in the treatment of epilepsy [255].”
Gaulin Homogenization: A Mechanistic Study
Lander, R., Manger, W., Scouloudis, M., Ku, A., Davis, C., & Lee, A. (2000) · Biotechnology Progress · doi:10.1021/bp990135c · Cited by 141 · cited 1×
“However, at higher processing temperatures lower particle sizes are obtained, due to the reduced viscosity of the lipid phase at high temperatures [175].”
Pardeshi, C. V., Rajput, P. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Drug Delivery · doi:10.3109/10717544.2012.752421 · Cited by 141 · cited 2×
“Apomorphine and ropinirole are other dopaminergic agonists, given through oral and intranasal routes, respectively, which have shown encouraging results in vitro, ex vivo and in vivo PD rat models [202].”
Tsai, M.-J., Huang, Y.-B., Wu, P.-C., Fu, Y.-S., Kao, Y.-R., Fang, J.-Y., & Tsai, Y.-H. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22285 · Cited by 137
Dang, H., Meng, M. H. W., Zhao, H., Iqbal, J., Dai, R., Deng, Y., & Lv, F. (2014) · Journal of Nanoparticle Research · doi:10.1007/s11051-014-2347-9 · Cited by 134 · cited 2×
“Luteolin (LU, 5,7,30,40-tetrahydroxyflavone) -loaded SLNs, synthesized by hot-microemulsion [217], have been shown to reduce oxidative stress in vivo in the management of neurodegenerative disorders.”
InfluentialTopal, G. R., Mészáros, M., Porkoláb, G., Szecskó, A., Polgár, T. F., Siklós, L., Deli, M. A., Veszelka, S., & Bozkir, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics13010038 · Cited by 132 · cited 1×
“Donepezil (an anti-Alzheimer’s drug), when tailored to ApoE-targeted and SLN-based formulations, the in vitro study findings showed that it has enhanced drug delivery with a favorable release profile in CMEC/D3 brain endothelial cells and human SH-SY5Y neuronal cells [223].”
Martins, S., Tho, I., Reimold, I., Fricker, G., Souto, E. B., Ferreira, D., & Brandl, M. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.054 · Cited by 129 · cited 1×
“However, the formulation has been used to stabilize the physiological pH and further stabilize size, charge, and pharmacokinetics using SLN modifications, showing better brain targeting efficacy [49,73–75].”
Adsorptive-Mediated Brain Delivery Systems
Lu, W. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112803341851 · Cited by 129 · cited 1×
“Hence the binding affinity of AMT is low, but the binding ability is high, with the same level of transcytosis efficiency as RMT [93,94].”
Etame, A. B., Diaz, R. J., O'Reilly, M. A., Smith, C. A., Mainprize, T. G., Hynynen, K., & Rutka, J. T. (2012) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.02.003 · Cited by 126 · cited 1×
“Moreover, there are several approaches developed to increase the permeability of the BBB such as injection of hyperosmolar mannitol [32] causing reversible disruption, or by providing ultrasound as physical stimulus [33,34].”
Astrocyte–endothelial interactions and blood–brain barrier permeability
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00047_13.x · Cited by 126
Blood Compatibility of Cetyl Alcohol/Polysorbate-Based Nanoparticles
Koziara, J. M., Oh, J. J., Akers, W. S., Ferraris, S. P., & Mumper, R. J. (2005) · Pharmaceutical Research · doi:10.1007/s11095-005-7547-7 · Cited by 125
In vitro and in vivo efficacy of edelfosine-loaded lipid nanoparticles against glioma
de Mendoza, A. E., Véronique Préat, A., Mollinedo, F., & Blanco‐Prieto, M. J. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.030 · Cited by 124 · cited 1×
“The results showed an anti-proliferative effect, with higher accumulation in the brain tissue, and a significant reduction in tumor growth [250].”
Novel Delivery Strategies for Glioblastoma
Zhou, J., Atsina, K.-B., Himes, B. T., Strohbehn, G. W., & Saltzman, W. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e318244d8ae · Cited by 124
Rawat, M. K., Jain, A., & Singh, S. K. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22435 · Cited by 123 · cited 1×
“Disadvantages of SLNs. • Poor drug loading due to limited space in the lipid matrix [64–67].”
Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes
Tabatt, K., Kneuer, C., Sameti, M., Olbrich, C., Müller, R. H., Lehr, C., & Bakowsky, U. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.029 · Cited by 123 · cited 1×
“As they are formed of a physiological solid lipid emulsion system by maximally avoiding organic solvents, they display better biocompatibility and reduced systemic toxicity in comparison to polymeric nanoparticles [46].”
Trends in the Molecular Pathogenesis and Clinical Therapeutics of Common Neurodegenerative Disorders
Choonara, Y. E., Pillay, V., Du Toit, L. C., Modi, G., Naidoo, D., Ndesendo, V. M. K., & Sibambo, S. R. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10062510 · Cited by 123 · cited 1×
“…are affected by various chronic neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), brain tumors/cancers, Huntington’s disease (HD), neuromuscular disease, multiple sclerosis (MS), neurodegeneration, and epilepsy, resulting in tremendous morbidity and mortality [1].”
Investigations on solid lipid nanoparticles prepared by precipitation in o/w emulsions
Siekmann, B., & Westesen, K. (1996) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 123
Nanoparticles for Brain-Specific Drug and Genetic Material delivery, Imaging and Diagnosis
Posadas, I., Monteagudo, S., & Ceña, V. (2016) · Nanomedicine · doi:10.2217/nnm.16.15 · Cited by 123 · cited 2×
“Either way, BBB disruption led to unavoidable influx neurotoxins causing significant damage to the brain [31].”
PHARMACOKINETICS OF DOXORUBICIN INCORPORATED IN SOLID LIPID NANOSPHERES (SLN)
Zara, G. P., Cavalli, R., Fundaro', A., Bargoni, A., Caputo, O., & Gasco, M. R. (1999) · Pharmacological Research · doi:10.1006/phrs.1999.0509 · Cited by 122 · cited 1×
“administration to rats showed lower drug concentration in the liver, heart, and kidneys, while a higher concentration was shown in the brain due to RES escaping, in comparison to free doxorubicin [79].”
Kadari, A., Pooja, D., Gora, R. H., Gudem, S., Kolapalli, V. R. M., Kulhari, H., & Sistla, R. (2018) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2018.09.012 · Cited by 122 · cited 1×
“One study showed that a SLN formulation of docetaxel functionalized with angiopep-2 can specifically bind to the LDL-receptor-related protein 1 (LRP1), which is overexpressed at the BBB, showing higher in vitro cytotoxicity and BBB permeability by receptor mediated endocytic processes [112].”
Zheng, G., Zheng, M., Yang, B., Fu, H., & Li, Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109006 · Cited by 120 · cited 1×
“(d) Conjugation of SLN with arginine-glycine-aspartic (RGD) Studies have showed that doxorubicin-SLN, when conjugated with RGD, increased in vitro antitumor efficacy and in vivo cytotoxicity in a target specific manner in comparison to non-targeted SLN [111].”
Vakilinezhad, M. A., Amini, A., Javar, H. A., Zarandi, B. F. B. B., Montaseri, H., & Dinarvand, R. (2018) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-018-0221-5 · Cited by 119
Jain, V. K., Gupta, A., Pawar, V. K., Asthana, S., Jaiswal, A. K., Dube, A., & Chourasia, M. K. (2014) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-014-1084-y · Cited by 115
Patel, M., Souto, E. B., & Singh, K. K. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.784742 · Cited by 114 · cited 2×
“The blood–brain barrier (BBB) plays a further vital role as an obstacle for the potential drugs to cross [5].”
Mosallaei, N., Jaafari, M. R., Hanafi‐Bojd, M. Y., Golmohammadzadeh, S., & Malaekeh‐Nikouei, B. (2013) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23522 · Cited by 114
Polymorphic properties of micronized carbamazepine produced by RESS
Gosselin, P. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00649-x · Cited by 113 · cited 1×
“Ex-SLN can be prepared in the presence of carbon dioxide (99.99%), then used as a solvent during the rapid expansion of the supercritical carbon dioxide solutions (RESS) method [182].”
InfluentialSolid lipid nanoparticles produced through a coacervation method
Battaglia, L., Gallarate, M., Cavalli, R., & Trotta, M. (2010) · Journal of Microencapsulation · doi:10.3109/02652040903031279 · Cited by 113
Novel Drug Delivery Strategies in Neuro-Oncology
Bidros, D. S., & Vogelbaum, M. A. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.04.004 · Cited by 112 · cited 1×
“An advanced nano-drug carrier system is a novel approach to delivering a specific anticancer drug in a target-specific manner without affecting the normal, healthy cells [244].”
Thöle, M., Nobmann, S., Huwyler, J., Bartmann, A., & Fricker, G. (2002) · Journal of Drug Targeting · doi:10.1080/10611860290031840 · Cited by 110 · cited 1×
“Another study showed that colloidal particles coupled to sterically stabilized cationized albumin have a better interaction with brain endothelial cells and higher intracellular accumulation [110].”
Targeting receptor-ligand chemistry for drug delivery across blood-brain barrier in brain diseases
Anthony, D. P., Hegde, M., Shetty, S. S., Rafic, T., Mutalik, S., & Rao, B. S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119326 · Cited by 110 · cited 1×
“Drug molecules modified with carrier molecules such as nanoparticles and liposomes can be delivered by the unique process of “tricking”, where the receptors mediate internalization and ligands bind target cells in brain tissue [36].”
Drug Delivery to the Ischemic Brain
Thompson, B. J., & Ronaldson, P. T. (2014) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.06.013 · Cited by 107 · cited 1×
“Gradually, brain edema, BBB damage, and nerve tissue damage result in associated disorders including neuronal cell death [260–262].”
Tan, M.-E., He, C.-H., Jiang, W., Zeng, C., Yu, N., Huang, W., Gao, Z., & Xing, J. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s131893 · Cited by 107 · cited 1×
“Hence, a combined process with a high temperature and high speed, along with ultrasonication, may ensure the production of quality SLNs [174].”
Gallarate, M., Trotta, M., Battaglia, L., & Chirio, D. (2008) · Journal of Microencapsulation · doi:10.1080/02652040802390156 · Cited by 105
Glorioso, C., Oh, S., Douillard, G. G., & Sibille, E. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.016 · Cited by 103
Manjunath, K., & Venkateswarlu, V. (2006) · Journal of Drug Targeting · doi:10.1080/10611860600888850 · Cited by 103 · cited 1×
“Manju-nath and Venkateswarlu [76] tried to improve the bioavailability of the antipsychotic drugs clozapine and nitrendipine through their various SLN formulations, using PEG and Tween 80.”
In Vitro and In Vivo Study of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide
Peira, E., Marzola, P., Podio, V., Aime, S., Sbarbati, A., & Gasco, M. R. (2003) · Journal of Drug Targeting · doi:10.1080/1061186031000086108 · Cited by 102
Bargoni, A., Cavalli, R., Zara, G. P., Fundaro', A., Caputo, O., & Gasco, M. R. (2001) · Pharmacological Research · doi:10.1006/phrs.2001.0813 · Cited by 101
Chirio, D., Gallarate, M., Peira, E., Battaglia, L., Muntoni, E., Riganti, C., Biasibetti, E., Capucchio, M. T., Valazza, A., Panciani, P. P., et al. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.10.017 · Cited by 100 · cited 1×
“SLNs loaded with paclitaxel and bevacizumab synthesized by the fatty acid coacervation technique, were found to penetrate the BBB (hCMEC/D3 cell monolayer in vitro BBB model) [253].”
Rajpoot, K., & Jain, S. K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2020.02.132 · Cited by 100 · cited 1×
“…studies are based on how to attaching a targeting ligand to an SLN, such as by linking a fatty acid of the NP to an amino group of the ligand [113], an amino group of a phospholipid to an acid group of the ligand [114], or an amino group of the chitosan coating to an acid group of the ligand [115].”
Critical Review of Lipid-Based Nanoparticles as Carriers of Neuroprotective Drugs and Extracts
Fernandes, F., Dias-Teixeira, M., Delerue-Matos, C. M., & Grosso, C. (2021) · Nanomaterials · doi:10.3390/nano11030563 · Cited by 99 · cited 1×
“Nonetheless, few of them have been approved in clinical context only in the treatment of cardiac diseases and some cancers, and not for neurological disorders in crossing the BBB [276,277].”
Chirio, D., Gallarate, M., Peira, E., Battaglia, L., Serpe, L., & Trotta, M. (2011) · Journal of Microencapsulation · doi:10.3109/02652048.2011.590615 · Cited by 98
Morel, S., Terreno, E., Ugazio, E., Aime, S., & Gasco, M. R. (1998) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(97)00107-0 · Cited by 97
Jumaa, M., & Müller, B. W. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(99)00071-8 · Cited by 96 · cited 1×
“Contrasting with the polymeric nanoparticles, lipid nanoparticles such as solid lipid nanoparticles (SLNs) are gaining considerable attention as a worldwide drug delivery system for various clinical purposes [39].”
Hassanzadeh, P., Arbabi, E., Atyabi, F., & Dinarvand, R. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.046 · Cited by 93 · cited 1×
“In ischemic rat models, neurobehavioral deficits were improved significantly by ferulic acid (FA) loaded NLC, with improved bioavailability and reduced oxidative stress and neurotoxicity [269].”
In vitro evaluation of idebenone-loaded solid lipid nanoparticles for drug delivery to the brain
Montenegro, L., Campisi, A., Sarpietro, M., Carbone, C., Acquaviva, R., Raciti, G., & Puglisi, G. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2010.539231 · Cited by 92 · cited 2×
“Idebenone is another antioxidant drug of choice, loaded into SLN as a potent drug delivery system to the brain [152,228].”
Chaichana, K. L., Pinheiro, L., & Brem, H. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.114 · Cited by 91 · cited 1×
“Drug-loaded polymeric biodegradable materials can be implanted for the sustained release of the drug at a specific site of the brain in this type of delivery strategy [22,23].”
Blood-Brain Barrier (BBB) Disruption Using a Diagnostic Ultrasound Scanner and Definity® in Mice
Bing, K. F., Howles, G. P., Qi, Y., Palmeri, M. L., & Nightingale, K. R. (2009) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2009.03.012 · Cited by 90 · cited 1×
“Moreover, there are several approaches developed to increase the permeability of the BBB such as injection of hyperosmolar mannitol [32] causing reversible disruption, or by providing ultrasound as physical stimulus [33,34].”
Ahlin, P., Kristl, J., & Šmid-Korbar, J. (1998) · Acta Pharmaceutica · Cited by 89
Effects of some experimental factors on the production process of solid lipid nanoparticles
Cavalli, R., Marengo, E., Rodrı́guez, L., & Gasco, M. R. (1996) · European Journal of Pharmaceutics and Biopharmaceutics · Cited by 89
Oyewumi, M. O., & Mumper, R. J. (2003) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(02)00587-2 · Cited by 84
Gao, Y., Gu, W., Chen, L., Xu, Z., & Li, Y. (2008) · Biomaterials · doi:10.1016/j.biomaterials.2008.07.008 · Cited by 83
Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders
Rakotoarisoa, M., & Angelova, A. (2018) · Medicines · doi:10.3390/medicines5040126 · Cited by 82 · cited 1×
“Most importantly, polymeric nanoparticles of a biocompatible and biodegradable nature are of essential interest for target-specific drug delivery [38].”
Between destiny and disease: Genetics and molecular pathways of human central nervous system aging
Glorioso, C., & Sibille, E. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.11.006 · Cited by 80 · cited 1×
“Central nervous system (CNS) diseases are most commonly characterized by an imbalance in neurological function, leading to neuronal death [2–4].”
Scaling up feasibility of the production of solid lipid nanoparticles (SLN).
Gohla, S., & Dingler, A. (2001) · PubMed · Cited by 78
Salmaso, S., Elvassore, N., Bertucco, A., & Caliceti, P. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21434 · Cited by 78
Frequency and Cause of Parkinson’s Disease
Rajput, A. H. (1992) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100041457 · Cited by 76
Preparation and in vitro evaluation of lipidic carriers and fillers for inhalation
Sebti, T., & Amighi, K. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.11.003 · Cited by 75
Gonçalves, M., Mignani, S., Rodrigues, J., & Tomás, H. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.016 · Cited by 75
Solid lipid nanoparticles loaded with lipoyl–memantine codrug: Preparation and characterization
Laserra, S., Basit, A., Sozio, P., Marinelli, L., Fornasari, E., Cacciatore, I., Ciulla, M., Türkez, H., Geyikoglu, F., & Di Stefano, A. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.03.001 · Cited by 72 · cited 2×
“Furthermore, LA and MEM were released as the end product of hydrolysis, exhibiting therapeutic efficacy in a safe and nontoxic manner [273].”
Research works printed but not linked: 7
- Dingler, A. (1998). Feste Lipid-Nanopartikel als Kolloidale Wirkstoffträgersysteme zur Dermalen Applikation. [Ph.D. Thesis, Freie Universität Berlin].
- Mehnert, 1998, Drug release and release mechanism of prednisolone loaded solid lipid nanoparticles, Pharmazie, 53, 552
- zur Muhlen, A. (1996). Feste Lipid Nanopartikel mit Prolongierter Wirkstoffliberation: Herstellung, Langzeitstabilität, Charakterisierung, Freisetzungsverhalten und Mechanismen. [Ph.D. Thesis, Free University of Berlin].
- Meyer, 1988, Wettkampf und Spiel in den Miniaturen der Manessischen Liederhandschrift, Stadion, 14, 1
- Nelluri, 2015, Formulation and evaluation of galantamine nanoparticles for neurological disorders, Int. J. Pharm. Chem. Biol. Sci., 5, 63
- Özdemir, Y.G., Pehlivan, S.B., and Sekerdag, E. (2017). Nanotechnology Methods for Neurological Diseases and Brain Tumors: Drug Delivery Across the Blood–Brain Barrier, Academic Press.
- Duarte, A.M.G. (2015). Resveratrol and Grape’s Extract-Loaded Solid Lipid Nanoparticles for the Treatment of Parkinson’s and Alzheimer’s Diseases. [Master’s Thesis, Faculty of Engineering of University of Porto].
Cited by
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Recent Progress in Nanostructured Smart Drug Delivery Systems for Cancer Therapy: A Review
Khan, M. I., Hossain, M. I., Hossain, M. K., Rubel, M. H. K., Hossain, K. M., Mahfuz, A. M. U. B., & Anik, M. I. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00002 · Cited by 370
Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles
Khairnar, S. V., Pagare, P., Thakre, A., Nambiar, A. R., Junnuthula, V., Abraham, M. C., Kolimi, P., Nyavanandi, D., & Dyawanapelly, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091886 · Cited by 263
“The spray-drying technique procedure is reproduced from [43].”
MethodAkombaetwa, N., Ilangala, A. B., Thom, L., Memvanga, P. B., Witika, B. A., & Buya, A. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020656 · Cited by 215
Correia, A. C., Monteiro, A. R., Silva, R., Moreira, J. N., Sousa Lobo, J. M., & Silva, A. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114485 · Cited by 206
Metadata
- Authors
- Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H.
- Affiliations
- Taipei Medical University (TW)
- Cathay General Hospital (TW)
- Taipei Medical University Hospital (TW)
- Birla Institute of Technology and Science, Pilani (IN)
- Corresponding author
- Yang, Chih-Hao
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2021-07-31
- Volume
- 13
- Issue
- 8
- Pages
- 1183
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC8402065
- OpenAlex
- W3187770666
- Cited by
- 318
- References
- 268
- Citations by year
- 2026: 64 · 2025: 95 · 2024: 70 · 2023: 55 · 2022: 30 · 2021: 4
- FWCI
- 2.75
- Type
- journal article
- Language
- en
- Update notices
- correction (2026-08-27)
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministry of Science and Technology, Taiwan (MOST-106-2320-B-038-049-MY3, MOST-108-2314-B-038-022)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Keywords
- solid lipid nanoparticles, blood-brain barrier, brain drug delivery, central nervous system disorders, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, brain tumors, epilepsy, ischemic stroke, nanoparticle synthesis, drug carriers, controlled drug delivery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.